Oncolytics Biotech
ONCY
37 hedge funds and large institutions have $2.79M invested in Oncolytics Biotech in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.02% less ownership
Funds ownership: 1.93% → 1.91% (-0.02%)
16% less funds holding
Funds holding: 44 → 37 (-7)
18% less capital invested
Capital invested by funds: $3.39M → $2.79M (-$600K)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$423K |
| 2 |
Morgan Stanley
New York
|
+$83.5K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$75.8K |
| 4 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$29.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARC
Advisor Resource Council
Dallas,
Texas
|
-$280K |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$120K |
| 3 |
Two Sigma Advisers
New York
|
-$117K |
| 4 |
VF
Virtu Financial
New York
|
-$98K |
| 5 |
Two Sigma Investments
New York
|
-$70K |
ONCY Hedge Fund Activity: Q3 2021 in Review
37 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2021, worth a combined $2.79M — down 18% from $3.39M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ONCY and 2 opened new positions — a net loss of 7 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $423K. The largest seller was Advisor Resource Council, exiting entirely with an estimated $280K sold.
- 37 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2021, down from 44 in Q2 2021.
- Funds reported $2.79M of Oncolytics Biotech stock for Q3 2021, down 18% quarter-over-quarter.
- 2 funds opened new Oncolytics Biotech positions in Q3 2021 and 9 closed out, a net change of -7 holders.
- The largest Oncolytics Biotech buyer in Q3 2021 was Renaissance Technologies, an estimated $423K added.
- The largest Oncolytics Biotech seller in Q3 2021 was Advisor Resource Council, an estimated $280K sold.
Based on aggregated 13F filings for Q3 2021.